Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIZ985 Alone or with Spartalizumab/Tislelizumab in Advanced Cancers
NCT04261439Phase 1Terminated
- Sponsor
- Novartis
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons
- Countries
- 7
01
Overview
Phase 1, open-label trial of NIZ985 in solid tumor and lymphoma (2 arms), sponsored by Novartis. Primary endpoints: Incidence of Dose Limiting Toxicities, Adverse Events at 24 months and 2 more. Started Feb 2020; status: terminated.
02
Drugs
NIZ985
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04261439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04261439.